newscontact us

CESCA THERAPEUTICS HIGHLIGHTS PROMISING DATA FOR THE TREATMENT OF CHRONIC NON-HEALING ULCERS

RANCHO CORDOVA, CA, March 15, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced encouraging data from a study evaluating the use of autologous platelet rich plasma(PRP) for the treatment of chronic non-healing ulcers…(more)